Positron emission tomography/magnetic resonance imaging with68Gallium-labeled ligand of prostate-specific membrane antigen: Promising novel option in prostate cancer imaging?

Sensitivity of PET/MRI to detect recurrence of prostate cancer

(2013) Patricia Arce-Calisaya et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Hybrid Positron Emission Tomography–Magnetic Resonance Imaging with Gallium 68 Prostate-specific Membrane Antigen Tracer: A Next Step for Imaging of Recurrent Prostate Cancer—Preliminary Results

(2013) Matthias C. Roethke et al.   EUROPEAN UROLOGY

The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis

(2013) Martin H. Umbehr et al.   EUROPEAN UROLOGY

Critical Evaluation of Magnetic Resonance Imaging Targeted, Transrectal Ultrasound Guided Transperineal Fusion Biopsy for Detection of Prostate Cancer

(2013) Timur H. Kuru et al.   JOURNAL OF UROLOGY

[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH

(2012) A. Afshar-Oromieh et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses

(2012) A. Drzezga et al.   JOURNAL OF NUCLEAR MEDICINE

A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer

(2012) Martin Schäfer et al.   EJNMMI Research